RxDoctor Payments Data

Michael Osleber, MD

MOHS-Micrographic Surgery · Little Rock, ARNPI 1003013384

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $685 and has fallen 63.6% since, to $249 in 2025.

$2,493in general payments, 2019–2025

Across 152 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$432
  • AbbVie$342
  • Johnson & Johnson$318
  • Regeneron Healthcare Solutions, Inc.$314
  • Sun Pharmaceutical Industries Inc.$251
  • Sanofi$139
  • plus $698 from 14 others
$2,825in ownership & investment interests, 2019–2025

Across 5 payments — averaging $565.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • Sitesaver Inc.$3K

What the payments were for

  • Food & beverage$2,493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few mohs-micrographic surgery providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,850,647
Medicare patients
1,891
Services billed
19,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluocinonide14$809
Ketoconazole44$803
Triamcinolone Acetonide59$569
Doxycycline Hyclate27$288
Mupirocin19$172
Hydrocortisone33$136
Cephalexin12$38

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →